Get the Stockscreener App
1.46
12.57%
-0.21
After Hours:
1.46
Pepgen Inc stock is traded at $1.46, with a volume of 137.62K.
It is down -12.57% in the last 24 hours and down -7.01% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
See More
Previous Close:
$1.67
Open:
$1.66
24h Volume:
137.62K
Relative Volume:
0.16
Market Cap:
$47.77M
Revenue:
-
Net Income/Loss:
$-87.23M
P/E Ratio:
-0.4916
EPS:
-2.97
Net Cash Flow:
$-82.77M
1W Performance:
+0.00%
1M Performance:
-7.01%
6M Performance:
-71.09%
1Y Performance:
-91.07%
1-Day Range:
$1.46
$1.67
1-Week Range:
$1.40
$1.7299
52-Week Range:
$0.8801
$19.30
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.46 | 48.10M | 0 | -87.23M | -82.77M | -2.97 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
PepGen price target lowered to $1 from $3 at BofA - Yahoo Finance
PepGen to discontinue DMD programs after PGN-EDO51 did not achieve target - Yahoo Finance
H.C. Wainwright cuts PepGen stock price target to $8, keeps Buy rating - Investing.com India
PepGen Inc.’s Strategic Shift to DM1 Program Earns Buy Rating Amid Promising Developments - TipRanks
PepGen (NASDAQ:PEPG) Price Target Lowered to $8.00 at HC Wainwright - Defense World
PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1 - MSN
PepGen (PEPG) Adjusts Focus After Discontinuing DMD Program | PE - GuruFocus
PepGen (PEPG) Shifts Focus from DMD as PGN-EDO51 Results Disappo - GuruFocus
PepGen (PEPG) Price Target Lowered by Analyst HC Wainwright & Co - GuruFocus
PepGen (PEPG) Faces Price Target Cut as Key Program Ends | PEPG Stock News - GuruFocus
PepGen Inc. Receives Buy Rating from Ananda Ghosh Due to Strategic Focus on Promising DM1 Program - TipRanks
PepGen Inc.’s Strategic Shift Amidst DMD Program Discontinuation and Competitive Challenges - TipRanks
PepGen price target lowered to $8 from $14 at H.C. Wainwright - TipRanks
PepGen (PEPG) Adjusts Focus After Discontinuing DMD Program | PEPG Stock News - GuruFocus
PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate - Benzinga
PepGen to discontinue development of experimental Duchenne therapy; shares drop - whbl.com
PepGen Inc. Discontinues DMD Programs After Trial Results - TipRanks
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update - Business Wire
PepGen appoints new CTO to advance therapies By Investing.com - Investing.com South Africa
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stoc - GuruFocus
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stock News - GuruFocus
PepGen appoints new CTO to advance therapies - Investing.com
PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer - New Castle News
PepGen Inc. (NASDAQ:PEPG) Holdings Lifted by Dimensional Fund Advisors LP - Defense World
PepGen Inc.’s Promising Advances in DMD and DM1 Programs Justify Buy Rating - TipRanks
PepGen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HC Wainwright Cuts PepGen (NASDAQ:PEPG) Price Target to $14.00 - Defense World
PepGen Inc. Reports Q1 2025 Financial Results - TipRanks
ATTENTION PEPG SHAREHOLDERS: Investors Who Lost Money on PepGen Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
PepGen stock price target cut to $14 from $16 by H.C. Wainwright - Investing.com Nigeria
PepGen (PEPG) Stock Target Price Lowered by HC Wainwright & Co. - GuruFocus
PepGen (PEPG) Price Target Adjusted by H.C. Wainwright Analyst | PEPG Stock News - GuruFocus
PepGen (PEPG) Price Target Adjusted by H.C. Wainwright Analyst | - GuruFocus
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - BioSpace
PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph
PepGen Inc. CEO Makes Bold Stock Purchase! - TipRanks
Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pepgen Inc Stock (PEPG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McArthur James G | President and CEO |
Apr 08 '25 |
Buy |
1.15 |
41,500 |
47,725 |
103,913 |
| DeLena Mary Beth | General Counsel |
Feb 26 '25 |
Sale |
1.68 |
1,432 |
2,406 |
1,568 |
| Donnelly Noel | Chief Financial Officer |
Feb 26 '25 |
Sale |
1.68 |
1,527 |
2,565 |
1,673 |
| Mellion Michelle L | Chief Medical Officer |
Jul 25 '24 |
Option Exercise |
10.21 |
7,571 |
77,300 |
7,571 |
| Mellion Michelle L | Chief Medical Officer |
Jul 24 '24 |
Option Exercise |
10.21 |
201 |
2,052 |
201 |
| Mellion Michelle L | Chief Medical Officer |
Jul 25 '24 |
Sale |
18.06 |
7,571 |
136,741 |
0 |
| Mellion Michelle L | Chief Medical Officer |
Jul 24 '24 |
Sale |
18.01 |
201 |
3,619 |
0 |
| Mellion Michelle L | Chief Medical Officer |
Jul 18 '24 |
Option Exercise |
10.21 |
12,625 |
128,901 |
12,625 |
| Mellion Michelle L | Chief Medical Officer |
Jul 18 '24 |
Sale |
18.20 |
12,625 |
229,804 |
0 |
| Mellion Michelle L | Chief Medical Officer |
Jul 16 '24 |
Option Exercise |
10.21 |
5,901 |
60,249 |
5,901 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):